Moreover, our data extended previous studies indicating that monoclonal antibodies targeting both IGF1R and HRs markedly inhibit the growth of thyroid and breast cancer cells with high HR:IGF1R ratios [27]. This evidence concerns the gene IGF1R and breast cancer.